Literature DB >> 19897560

Inhibition of neutrophil elastase-induced goblet cell metaplasia by tiotropium in mice.

N Arai1, M Kondo, T Izumo, J Tamaoki, A Nagai.   

Abstract

Airway occlusion by mucus in chronic obstructive disease (COPD) is associated with a poor prognosis. We hypothesised that tiotropium has the ability to inhibit neutrophil elastase (NE)-induced goblet cell metaplasia in mice and mucin production in vitro. On days 1, 4, and 7, tiotropium or vehicle was administered to C57BL/6 mice by inhalation and they were allowed to intranasally aspirate human NE. Bronchoalveolar lavage fluid (BALF) and lung sections were analysed on days 8, 11 and 14. The effect of late administration of tiotropium on the goblet cell metaplasia by NE aspiration was also assessed. NE-induced MUC5AC production by NCI-H292 cells was measured with ELISA. Repeated NE aspiration induced marked goblet cell metaplasia. The grading of goblet cell metaplasia, neutrophil count and eosinophil count in BALF, keratinocyte-derived chemokine level and leukotriene B(4) level in BALF, and M(3) receptor expression by immunohistochemistry, were lower in the tiotropium group than in the vehicle group. Late administration of tiotropium inhibited the established goblet cell metaplasia. Tiotropium inhibited NE-induced MUC5AC production. Tiotropium inhibited NE-induced goblet cell metaplasia and mucin production, probably mediated by suppression of inflammation and a direct action on epithelial cells. This result suggests that tiotropium may be useful for the treatment of mucus overproduction in COPD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19897560     DOI: 10.1183/09031936.00040709

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  30 in total

1.  MiR-146a negatively regulates neutrophil elastase-induced MUC5AC secretion from 16HBE human bronchial epithelial cells.

Authors:  Tian Zhong; Juliy M Perelman; Victor P Kolosov; Xiang-dong Zhou
Journal:  Mol Cell Biochem       Date:  2011-07-20       Impact factor: 3.396

Review 2.  Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases.

Authors:  Khuder Alagha; Alain Palot; Tunde Sofalvi; Laurie Pahus; Marion Gouitaa; Celine Tummino; Stephanie Martinez; Denis Charpin; Arnaud Bourdin; Pascal Chanez
Journal:  Ther Adv Chronic Dis       Date:  2014-03       Impact factor: 5.091

3.  Chronic exposure to perfluorinated compounds: Impact on airway hyperresponsiveness and inflammation.

Authors:  Min H Ryu; Aruni Jha; Oluwaseun O Ojo; Thomas H Mahood; Sujata Basu; Karen A Detillieux; Neda Nikoobakht; Charles S Wong; Mark Loewen; Allan B Becker; Andrew J Halayko
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-09-12       Impact factor: 5.464

Review 4.  Targeting mucus hypersecretion: new therapeutic opportunities for COPD?

Authors:  Clémence Martin; Justine Frija-Masson; Pierre-Régis Burgel
Journal:  Drugs       Date:  2014-07       Impact factor: 9.546

5.  Human neutrophil elastase-mediated goblet cell metaplasia is attenuated in TACE-deficient mice.

Authors:  Jin-Ah Park; Asma S Sharif; Tetsuya Shiomi; Lester Kobzik; David I Kasahara; Daniel J Tschumperlin; Judith Voynow; Jeffrey M Drazen
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-04-05       Impact factor: 5.464

Review 6.  Long-Acting Muscarinic Antagonists for Difficult-to-Treat Asthma: Emerging Evidence and Future Directions.

Authors:  Adeeb Bulkhi; Farnaz Tabatabaian; Thomas B Casale
Journal:  Drugs       Date:  2016-07       Impact factor: 9.546

7.  PPARγ as a Potential Target to Treat Airway Mucus Hypersecretion in Chronic Airway Inflammatory Diseases.

Authors:  Yongchun Shen; Lei Chen; Tao Wang; Fuqiang Wen
Journal:  PPAR Res       Date:  2012-06-17       Impact factor: 4.964

Review 8.  Muscarinic receptors and their antagonists in COPD: anti-inflammatory and antiremodeling effects.

Authors:  George Karakiulakis; Michael Roth
Journal:  Mediators Inflamm       Date:  2012-11-24       Impact factor: 4.711

9.  Inhaled tiotropium to prevent postoperative cardiopulmonary complications in patients with newly diagnosed chronic obstructive pulmonary disease requiring lung cancer surgery.

Authors:  Takashi Nojiri; Masayoshi Inoue; Kazuhiro Yamamoto; Hajime Maeda; Yukiyasu Takeuchi; Tomoyuki Nakagiri; Yasushi Shintani; Masato Minami; Noriyoshi Sawabata; Meinoshin Okumura
Journal:  Surg Today       Date:  2013-01-10       Impact factor: 2.549

Review 10.  Ten years of tiotropium: clinical impact and patient perspectives.

Authors:  Abebaw M Yohannes; Martin J Connolly; Nicola A Hanania
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2013-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.